Skip to main content
OpenTrials
Completed

NCT Number: NCT05733624

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The Catholic University of korea, Bucheon ST.Mary's Hospital, Bucheon-si, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and Female who over 19 years old
  • Those who have dry eye symptoms (Dryness, Grittiness, soreness, irritation, watering, etc.)
  • Those who meet below criteria at least one of two eyes;
  • Those who have over than score 2 in corneal staining test-Oxford grading
  • Tear secretion test without anesthesia(Schirmer test) result would be under 10mm/5min (If the test result is 0mm/5min, it should be over than 3mm/5min on the nasal stimulation schirmer test in the same eye)
  • TBUT(Tear film break-up time) test result should be under 10sec.
  • The corrected visual acuity is 0.2 or more.

Exclusion criteria

  • Those who have clinically significant eye disease not related to dry eye syndrome
  • Those who are in medication of systemic steroid or immunosuppressant 90days before screening visit
  • Those who have worn contact lenses before 72hours or have to wear contact lenses or disagree not to wear contact lenses during study period
  • Those who have medical history with intraocular surgery 12months before screening visit
  • Those who have diagnosed with glaucoma or have an intraocular pressure over than 21mmHg at least in one of the eyes
  • Those who have medicated cyclosporine eye-drops 6weeks before screening visit
  • Those who have underwent any eye correction surgery such as LASIK(Laser-assistant in situ keratomileusis) 12 months before screening visit
  • Those who have underwent a silicone lacrimal punctal occlusion or cauterization of the punctum excluding collagen lacrimal punctal occlusion 90 days before screening visit
  • Those who have received other investigational drugs/devices 30 days before screening visit
  • Those who are inappropriate for participating in this study according to investigator's judgement

Treatment and study plan

SCAI-001 0.01% eyedrop

Drug

BID for 12weeks

Other names: Cyclosporine 0.01%

SCAI-001 0.02% eyedrop

Drug

BID for 12weeks

Other names: Cyclosporine 0.02%

Restasis 0.05% eyedrop

Drug

BID for 12weeks

Other names: Cyclosporine 0.05%

Primary outcomes

  1. Tear volume

    Time frame: Change from baseline at 12 weeks

    Schirmer's test

Secondary outcomes

  1. Tear volume

    Time frame: Change from baseline at 4, 8 weeks

    Schirmer's test

  2. Corneal staining score with fluorescein

    Time frame: Change from baseline at 4, 8, 12 weeks

    Oxford grading

  3. conjunctival staining score with Lissamine green

    Time frame: Change from baseline at 4, 8, 12 weeks

    Oxford grading

  4. Tear film break-up time

    Time frame: Change from baseline at 4, 8, 12 weeks

    Measured three times and recorded up to 1/100

  5. Standard patient evaluation of eye dryness questionnaire

    Time frame: Change from baseline at 4, 8, 12 weeks

    written by the subject

  6. Ocular surface disease index

    Time frame: Change from baseline at 4, 8, 12 weeks

    written by the subject

  7. Total number of rescue medication used

    Time frame: 12weeks

    sourced by patient diary

Sponsors and collaborators

Lead sponsor

SCAI Therapeutics

Industry

Registry information

Official study title

A Multicenter, Active Control, Parallel Group, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops in Patients With Dry Eye Disease

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Feb 17, 2023
Registry last updated
Feb 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.